Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GLP-1RA Clear all
Active, not recruiting Phase 2Phase 3 Interventional

Triple Therapy in T1DM

NCT03899402
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Not yet recruiting Not applicable Interventional

Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation

NCT07784127
View directory record Official record
Conditions
Diabetes
Interventions
Gut motility quantification using a capsule after initiating GLP-1RA therapy
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Recruiting Early Phase 1 Interventional

GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

NCT06338553
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Semaglutide (Rybelsus®), Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 23, 2026, 10:08 AM EDT
Recruiting Phase 2 Interventional

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

NCT07107334
View directory record Official record
Conditions
Endometrioid Endometrial Adenocarcinoma
Interventions
Glucagon-like peptide 1 receptor agonist
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

NCT07575932
View directory record Official record
Conditions
Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity, Overnutrition, Nutrition Disorders, Nutritional and Metabolic Diseases, Body Weight
Interventions
PF-08653945, PF-08653944, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
53
States / cities
Sun City West, Arizona • Canoga Park, California • Fountain Valley, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity

NCT02496611
View directory record Official record
Conditions
Severe Obesity
Interventions
Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Oct 23, 2026, 10:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of GLP-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior

NCT07611201
View directory record Official record
Conditions
Obesity, Overweight, Taste Perception, Olfaction, Eating Behavior, Appetite
Interventions
Not listed
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Terminated Phase 2 Interventional

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

NCT05297045
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RGT001-075, Placebo
Drug · Other
Lead sponsor
Regor Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Doral, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 23, 2026, 10:08 AM EDT
Not listed Not applicable Interventional

Transform CV Risk in Diabetes

NCT05948969
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Decision support, Facilitated referral to a cardiometabolic team-based center
Other
Lead sponsor
American College of Cardiology
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 23, 2026, 10:08 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

NCT07311850
View directory record Official record
Conditions
Obesity and Overweight
Interventions
MET097, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Scottsdale, Arizona • Canoga Park, California • Oxnard, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Gestational Response, Outcomes, and Weight After GLP-1 Use

NCT07743567
View directory record Official record
Conditions
Pregnant Individuals, Obesity & Overweight, Gestational Weight Gain
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Recruiting Phase 3 Interventional

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

NCT07575399
View directory record Official record
Conditions
Obesity or Overweight
Interventions
Maridebart Cafraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
53
States / cities
Pelham, Alabama • Chandler, Arizona • Sun City, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women

NCT07422987
View directory record Official record
Conditions
Body Composition, Muscle Function, GLP-1, Estrogen Level
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 60 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Completed No phase listed Observational Results available

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

NCT05214573
View directory record Official record
Conditions
Type 2 Diabetes, Cardiac Disease
Interventions
Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor, Sulfonylurea
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
386,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 23, 2026, 10:08 AM EDT
Active, not recruiting No phase listed Observational

Comparison of Body Composition Changes With Weight Loss Interventions

NCT07115069
View directory record Official record
Conditions
Obesity
Interventions
GLP-1 receptor agonist, Gastric Bypass Surgery (laparoscopic), Gastric Bypass Surgery (robotic)
Drug · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Active, not recruiting No phase listed Observational

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

NCT07188545
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 23, 2026, 10:08 AM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
View directory record Official record
Conditions
Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
781,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Active, not recruiting Not applicable Interventional

Acupressure Wristbands for GLP-1RA Related Nausea

NCT06939517
View directory record Official record
Conditions
Nausea
Interventions
SeaBand
Device
Lead sponsor
Florencia Ziemke
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Jupiter, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 23, 2026, 10:08 AM EDT
Not yet recruiting Not applicable Interventional

Digital Resistance Training for Midlife Women Using GLP-1

NCT07787533
View directory record Official record
Conditions
Women's Health, Obesity & Overweight, Perimenopausal Women, Digital Intervention, Behavior Change, glp1 Agonist, Resistance Exercise
Interventions
PLAN-RT 1.0
Behavioral
Lead sponsor
Louisiana State University and A&M College
Other
Eligibility
40 Years to 59 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Completed No phase listed Observational Results available

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

NCT05073692
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Diseases
Interventions
SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 85 Years
Enrollment
241,981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Pasadena, California • Pleasanton, California • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 23, 2026, 10:08 AM EDT
Recruiting Phase 2 Interventional

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

NCT06582875
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney, Obesity
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 23, 2026, 10:08 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

NCT07723833
View directory record Official record
Conditions
Healthy Participants
Interventions
Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Not yet recruiting No phase listed Observational

GLP-1 Impacts on Weight Management

NCT07829016
View directory record Official record
Conditions
Weight Management, Disordered Eating Behaviors
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 10:08 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

NCT07400653
View directory record Official record
Conditions
Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2, Type 2 Diabetes
Interventions
PF-08653944, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
55
States / cities
Anaheim, California • Canoga Park, California • Cerritos, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 10:08 AM EDT